Published in FEBS Lett on October 13, 2000
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol Rev (2009) 3.18
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A (2003) 1.76
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 1.28
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One (2010) 1.25
Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol (2001) 1.25
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem (2011) 1.17
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J (2001) 1.14
RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. EMBO J (2010) 1.12
Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol (2002) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol (2001) 1.07
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) (2007) 1.07
Promiscuous activation of transient receptor potential vanilloid 1 (TRPV1) channels by negatively charged intracellular lipids: the key role of endogenous phosphoinositides in maintaining channel activity. J Biol Chem (2013) 1.06
Identification of a binding motif in the S5 helix that confers cholesterol sensitivity to the TRPV1 ion channel. J Biol Chem (2011) 1.05
Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci (2015) 1.04
Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res (2010) 1.04
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Functionally important amino acid residues in the transient receptor potential vanilloid 1 (TRPV1) ion channel--an overview of the current mutational data. Mol Pain (2013) 1.01
Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol (2009) 1.01
Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br J Pharmacol (2005) 1.00
Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J (2002) 0.99
AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol (2006) 0.99
Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. J Pharmacol Exp Ther (2008) 0.96
The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. Br J Pharmacol (2011) 0.96
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol (2005) 0.94
The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro. J Physiol (2003) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem Neurosci (2012) 0.93
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol (2006) 0.93
Endocannabinoid-dependent LTD in a nociceptive synapse requires activation of a presynaptic TRPV-like receptor. J Neurophysiol (2010) 0.93
N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91
TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception. Cereb Cortex (2011) 0.91
Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem (2012) 0.91
Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci (2007) 0.91
Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem (2011) 0.91
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res (2007) 0.91
Effects of opioids, cannabinoids, and vanilloids on body temperature. Front Biosci (Schol Ed) (2011) 0.90
Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br J Pharmacol (2003) 0.87
N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn. Br J Pharmacol (2010) 0.86
Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.86
Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci (2007) 0.85
The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. J Neurochem (2009) 0.85
Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. PLoS One (2013) 0.85
A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons. Neuropharmacology (2005) 0.84
Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol (2010) 0.84
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol (2006) 0.83
Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. Br J Pharmacol (2007) 0.83
Acetaminophen modulation of hydrocodone reward in rats. Pharmacol Biochem Behav (2011) 0.83
Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat (2008) 0.83
Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur J Neurosci (2006) 0.83
Opportunistic activation of TRP receptors by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular communication. Life Sci (2012) 0.82
Binding mode pediction of evodiamine within vanilloid receptor TRPV1. Int J Mol Sci (2012) 0.82
2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J (2006) 0.81
AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. J Psychopharmacol (2013) 0.81
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem (2014) 0.81
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation. Curr Neuropharmacol (2016) 0.80
The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics (2015) 0.80
2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology (Berl) (2015) 0.79
Effect of olvanil and anandamide on vagal C-fiber subtypes in guinea pig lung. Br J Pharmacol (2005) 0.79
Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region. J Neurophysiol (2008) 0.79
Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels. Br J Pharmacol (2014) 0.77
Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Curr Neuropharmacol (2010) 0.77
Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. J Lipid Res (2008) 0.77
Leucettamols, bifunctionalized marine sphingoids, act as modulators of TRPA1 and TRPM8 channels. Mar Drugs (2012) 0.77
Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys. Psychopharmacology (Berl) (2016) 0.76
Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One (2013) 0.76
Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity. Pharmacol Res (2016) 0.76
A systems pharmacology perspective on the clinical development of Fatty Acid amide hydrolase inhibitors for pain. CPT Pharmacometrics Syst Pharmacol (2014) 0.76
Heat Sensing Receptor TRPV1 Is a Mediator of Thermotaxis in Human Spermatozoa. PLoS One (2016) 0.75
Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. Anesth Pain Med (2016) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Hydrogen peroxide mediates amyloid beta protein toxicity. Cell (1994) 5.19
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol (2000) 3.57
Preliminary experiments on the chemistry and pharmacology of cannabis. Nature (1970) 3.41
TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature (2002) 3.23
Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol (2001) 2.88
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci (2002) 2.43
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci (1998) 2.18
Endocannabinoids. Eur J Pharmacol (1998) 2.17
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem (2001) 2.13
Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain (2000) 2.11
Anaerobic Formation of Fumaric Acid by the Mold Rhizopus nigricans. J Bacteriol (1948) 2.09
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 2.07
Preliminary Experiments on a Microbial Fuel Cell. Science (1962) 1.90
The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol (1972) 1.86
Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol (2005) 1.86
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) (2007) 1.85
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77
Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet (2003) 1.74
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem (1997) 1.72
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther (1999) 1.67
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci (1996) 1.66
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol (1997) 1.61
Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett (1998) 1.58
Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci (2001) 1.58
Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun (1999) 1.58
Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett (1995) 1.57
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J (1997) 1.57
Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem (2000) 1.56
Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br J Pharmacol (1972) 1.56
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J (2000) 1.55
Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol (2001) 1.54
Anandamide may mediate sleep induction. Nature (1997) 1.53
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A (1998) 1.53
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr Med Chem (1999) 1.51
Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology (2004) 1.48
Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids (2002) 1.46
Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex (2007) 1.45
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem (2001) 1.43
Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem (1999) 1.42
Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A (2001) 1.41
Output factors for blocked fields. Br J Radiol (1992) 1.39
Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther (2004) 1.38
The variation of wedge factors with field size on a linear accelerator with wedge tray beneath secondary collimators. Br J Radiol (1991) 1.38
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol (1999) 1.37
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun (1999) 1.35
Characterisation of a human acid-sensing ion channel (hASIC1a) endogenously expressed in HEK293 cells. Pflugers Arch (2001) 1.35
Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem (2000) 1.34
Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology (2000) 1.34
Patient compliance with antihypertensive medication. Am J Public Health (1980) 1.34
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J (2000) 1.32
Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (1998) 1.32
Voltage- and time-dependent properties of the recombinant rat vanilloid receptor (rVR1). J Physiol (2000) 1.32
The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol (2005) 1.31
IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol (2006) 1.30
Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett (2001) 1.30
Neurotic illness in the families of children with asthma and wheezy bronchitis: a general practice population study. Psychol Med (1977) 1.28
Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 1.28
New perspectives on enigmatic vanilloid receptors. Trends Neurosci (2000) 1.28
Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci (2006) 1.28
Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun (1997) 1.27
Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett (1999) 1.27
Anandamide: some like it hot. Trends Pharmacol Sci (2001) 1.27
Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol (1997) 1.26